# Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

> **NCT03204396** · PHASE2 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 256 (actual)

## Conditions studied

- Glucagon-like Peptide-1
- Smoking Cessation
- Weight Change, Body
- Craving

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])

## Key facts

- **NCT ID:** NCT03204396
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-26
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03204396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03204396, "Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03204396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*